South Korea This week the Korean Ministry of Food and Drug Safety announced that as of 12th March 2019 a revised narcotics bill will go into effect that will allow imports of medical cannabis for self-treatment but under strict conditions. Until now, the import, export, manufacturing and sale of cannabis has been…
China It has been announced by China’s State Council that as of March 1st 2019, the government will reduce the VAT on a “first batch” of 21 rare disease drugs and four active pharmaceutical ingredients (API’s) by more than 80% in a bid to get new treatments to market faster. Historically, China has…
China This is the first in a series of articles examining what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging markets. We start in China, where the heads of Merck, Ipsen, Chiesi, Gedeon Richter and AbbVie’s Chinese affiliates give their…
Korea Looking at what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging markets. DHR International’s Helen Park outlines what she looks for in potential candidates for country manager positions in South Korea. What are the qualities you look for…
China Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. Together with his colleague Sarah Hassan, a researcher at the company they look at China’s skyrocketing health industry and what to expect from it in the Year of the Pig, 2019. China approved a record 48 new drugs last year, despite a significant organizational restructuring.…
China Even though China’s pharmaceutical sector remains largely generics-based, the Middle Kingdom’s biotechnology scene has been flourishing in recent years. Now the world’s fastest-growing biopharmaceutical market, China can boast a much-improved context in terms of drug regulation, ease of doing business, research capabilities and access to capital. Below, we highlight 5…
Malaysia After 61 years of single-party rule, the May 2018 electoral victory of the populist Pakatan Harapan (PH) coalition sent shockwaves through the Malaysian political landscape. This has been keenly felt within the healthcare sphere, where industry players are broadly supportive of PH’s plans to increase low-income Malaysians’ access to treatments…
India Dilip Shah, the Secretary-General of the Indian Pharmaceutical Alliance advocates for a stronger and more empowered regulator in India if the country is to build public confidence in its pharma output and drug inspectors. Improving the image of drug inspectors- will require investments in “infrastructure”. The key elements of this…
China In late 2018 China adopted a novel procurement scheme with the aim of dramatically cutting the amount being paid for generic drugs. The policy’s effect on pricing stands to hit domestic generic firms hardest unless they adapt their business models. Big Pharma could also lose out as their off-patent originators…
Korea This week, the Korean Ministry of Food and Drug Safety announced that it would enhance drug safety management and make a new, streamlined review process for advanced healthcare goods. The new process will tighten control on raw drug materials, expand patient compensation for side-effects, and prepare review systems for advanced…
Korea The administration of President Moon Jae-in is moving to ensure the enduring success of South Korea’s healthcare and life sciences industries through increased international collaboration. However, some pharma insiders are calling for even greater governmental support for what is still a tightly regulated sector facing pressures over pricing, exacerbated partly…
Samsung Biologics It was less than a decade ago (2011) that Samsung Biologics was a new kid on the block amongst Korea’s booming biotech conglomerates. Since then the company has snowballed, building a series of progressively larger, more advanced facilities, culminating in its 180,000L “Dream Plant.” This facility, the largest single plant…
See our Cookie Privacy Policy Here